Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.000951474785918254 -0.0342530922930543 -0.000951474785918254 -0.00209324452902011
Stock impact report

Acceleron Reports First Quarter 2020 Operating and Financial Results

Acceleron Pharma Inc. (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
Company Research Source: Business Wire
- REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS) -- REBLOZYL received positive CHMP opinion for the treatment of adults with transfusion-dependent anemia in lower-risk MDS and beta-thalassemia -- Pivotal Phase 3 MEDALIST and BELIEVE trial results published in New England Journal of Medicine -- Sotatercept granted Breakthrough Therapy designation by FDA and Priority Medicines (PRIME) designation by EMA for the treatment of patients with pulmonary arterial hypertension (PAH) -- PULSAR Phase 2 topline results are expected to be presented in an American Thoracic Society (ATS) 2020 web-based conference session by the end of June 2020 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare Show less Read more
Impact Snapshot
Event Time:
XLRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for XLRN alerts
Opt-in for
XLRN alerts

from News Quantified
Opt-in for
XLRN alerts

from News Quantified